Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.

Vasilyeva I, Mariandyshev A, Kazennyy B, Davidavičienė E, Lounis N, Keim S; TMC207TBC3001 study group.

Eur Respir J. 2019 May 16. pii: 1802208. doi: 10.1183/13993003.02208-2018. [Epub ahead of print] No abstract available.

PMID:
31097518
2.

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.

Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.

PLoS One. 2018 Jul 19;13(7):e0200539. doi: 10.1371/journal.pone.0200539. eCollection 2018.

3.

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.

Stevens M, Rusch S, DeVincenzo J, Kim YI, Harrison L, Meals EA, Boyers A, Fok-Seang J, Huntjens D, Lounis N, Mari N K, Remmerie B, Roymans D, Koul A, Verloes R.

J Infect Dis. 2018 Jul 24;218(5):748-756. doi: 10.1093/infdis/jiy227.

PMID:
29684148
4.

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1612-1615. doi: 10.1164/rccm.201704-0796LE. No abstract available.

5.

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.

Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K.

J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.

6.

A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome.

Boizard F, Brunchault V, Moulos P, Breuil B, Klein J, Lounis N, Caubet C, Tellier S, Bascands JL, Decramer S, Schanstra JP, Buffin-Meyer B.

Sci Rep. 2016 Oct 3;6:34453. doi: 10.1038/srep34453.

7.
8.

A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A.

J Clin Microbiol. 2016 Dec;54(12):2956-2962. Epub 2016 Sep 21.

9.

In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis.

Lounis N, Vranckx L, Gevers T, Kaniga K, Andries K.

Med Mal Infect. 2016 Jun;46(4):220-5. doi: 10.1016/j.medmal.2016.04.007.

PMID:
27210281
10.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

11.

Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.

Torrea G, Coeck N, Desmaretz C, Van De Parre T, Van Poucke T, Lounis N, de Jong BC, Rigouts L.

J Antimicrob Chemother. 2015 Aug;70(8):2300-5. doi: 10.1093/jac/dkv117. Epub 2015 May 14.

PMID:
25977401
12.

Multidrug-resistant tuberculosis and bedaquiline.

Diacon AH, Lounis N, Dannemann B.

N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235. No abstract available.

PMID:
25517714
13.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group.

N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.

14.

Acquired resistance of Mycobacterium tuberculosis to bedaquiline.

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A.

PLoS One. 2014 Jul 10;9(7):e102135. doi: 10.1371/journal.pone.0102135. eCollection 2014.

15.

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A.

Antimicrob Agents Chemother. 2012 Aug;56(8):4131-9. doi: 10.1128/AAC.00273-12. Epub 2012 May 21.

16.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF.

Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6. doi: 10.1128/AAC.06126-11. Epub 2012 Mar 5.

17.

Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K.

Antimicrob Agents Chemother. 2012 Mar;56(3):1444-51. doi: 10.1128/AAC.00720-11. Epub 2011 Dec 12.

18.

Endothelial function and mechanical arterial properties in children born small for gestational age: comparison with obese children.

Jouret B, Dulac Y, Bassil Eter R, Taktak A, Cristini C, Lounis N, Molinas C, Salles JP, Arnaud C, Acar P, Tauber M.

Horm Res Paediatr. 2011;76(4):240-7. doi: 10.1159/000329379. Epub 2011 Sep 7.

PMID:
21912079
19.

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V.

PLoS One. 2011 Mar 3;6(3):e17556. doi: 10.1371/journal.pone.0017556.

20.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657. Review.

PMID:
21270886
21.

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.

Andries K, Gevers T, Lounis N.

Antimicrob Agents Chemother. 2010 Nov;54(11):4540-4. doi: 10.1128/AAC.00934-10. Epub 2010 Aug 16.

22.

Essentiality of FASII pathway for Staphylococcus aureus.

Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A.

Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.

PMID:
20090698
23.

[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].

Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K.

Med Mal Infect. 2010 Jul;40(7):383-90. doi: 10.1016/j.medmal.2009.09.007. Epub 2009 Dec 1. Review. French.

PMID:
19954909
24.

ATP synthase inhibition of Mycobacterium avium is not bactericidal.

Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K.

Antimicrob Agents Chemother. 2009 Nov;53(11):4927-9. doi: 10.1128/AAC.00689-09. Epub 2009 Sep 8.

25.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.

N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.

26.

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Am J Respir Crit Care Med. 2009 Jan 1;179(1):75-9. doi: 10.1164/rccm.200711-1736OC. Epub 2008 Oct 23.

PMID:
18948422
27.

Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.

Lounis N, Gevers T, Van Den Berg J, Andries K.

Antimicrob Agents Chemother. 2008 Oct;52(10):3568-72. doi: 10.1128/AAC.00566-08. Epub 2008 Jul 21.

28.

Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207.

Lounis N, Gevers T, Van Den Berg J, Verhaeghe T, van Heeswijk R, Andries K.

J Clin Microbiol. 2008 Jul;46(7):2212-5. doi: 10.1128/JCM.00177-08. Epub 2008 May 14.

29.

[Growth follow-up of SGA children after 3 years of GH treatment].

Edouard T, Oliver I, Jouret B, Lounis N, Moulin P, Pienkowski C, Elefterion M, Salles JP, Tauber M.

Arch Pediatr. 2008 Feb;15(2):115-21. doi: 10.1016/j.arcped.2007.10.021. Epub 2008 Jan 18. French.

PMID:
18207714
30.

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.

Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5. Epub 2006 Dec 18.

31.

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7. Epub 2006 Sep 5.

32.

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V.

Antimicrob Agents Chemother. 2005 Oct;49(10):4015-9.

33.

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J.

Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93.

34.

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V.

Science. 2005 Jan 14;307(5707):223-7. Epub 2004 Dec 9.

35.

In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections.

Lounis N, Roscigno G.

Curr Pharm Des. 2004;10(26):3229-38. Review.

PMID:
15544512
36.

Wrist anomalies in Turner syndrome compared with Leri-Weill dyschondrosteosis: a new feature in Turner syndrome.

Tauber M, Lounis N, Coulet J, Baunin C, Cahuzac JP, Rochiccioli P.

Eur J Pediatr. 2004 Aug;163(8):475-81. Epub 2004 Jun 9.

PMID:
15197587
37.

Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up.

Tauber M, Jouret B, Cartault A, Lounis N, Gayrard M, Marcouyeux C, Pienkowski C, Oliver I, Moulin P, Otal P, Joffre F, Arnaud C, Rochiccioli P.

J Clin Endocrinol Metab. 2003 Nov;88(11):5101-6.

PMID:
14602733
38.

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N.

Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22.

39.

Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.

Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ.

Int J Tuberc Lung Dis. 2003 Jun;7(6):575-9.

PMID:
12797701
40.

Can some growth hormone (GH)-deficient children benefit from combined therapy with gonadotropin-releasing hormone analogs and GH? Results of a retrospective study.

Tauber M, Berro B, Delagnes V, Lounis N, Jouret B, Pienkowski C, Oliver I, Rochiccioli P.

J Clin Endocrinol Metab. 2003 Mar;88(3):1179-83.

PMID:
12629103
41.

Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice.

Lounis N, Ji B, Truffot-Pernot C, Ridley RG, Alber G, Grosset JH.

Clin Microbiol Infect. 1999 Jun;5(6):331-338.

42.

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.

Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J.

Antimicrob Agents Chemother. 2001 Dec;45(12):3482-6.

43.

Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J.

Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30.

44.

Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J.

Antimicrob Agents Chemother. 2001 Nov;45(11):3109-12.

45.

Experimental results on chloroquine and AIDS-related opportunistic infections.

Boelaert JR, Appelberg R, Gomes MS, Blasi E, Mazzolla R, Grosset J, Lounis N, Soteriadou K, Thiakaki M, Taramelli D, Tognazioli C.

J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):300-1. No abstract available.

PMID:
11242206
46.

Iron and Mycobacterium tuberculosis infection.

Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR.

J Clin Virol. 2001 Feb;20(3):123-6. Review.

PMID:
11166659
47.

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.

Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J.

Am J Respir Crit Care Med. 2000 May;161(5):1572-7.

PMID:
10806157
48.

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J.

Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9.

49.

Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.

Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B.

Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1436-40.

PMID:
9603120
50.

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice.

Lounis N, Ji B, Truffot-Pernot C, Grosset J.

Antimicrob Agents Chemother. 1997 May;41(5):1168-9.

Supplemental Content

Loading ...
Support Center